As the COVID-19 pandemic rages on, researchers are working overtime to develop vaccines and therapies to thwart SARS-CoV-2, the virus responsible for the disease Many efforts focus on the coronavirus spike protein, which binds the angiotensin-converting enzyme 2 (ACE2) on human cells to allow viral entry. Now, researchers reporting in ACS Central Science have uncovered an active role for glycans—sugar molecules that can decorate proteins—in this process, suggesting targets for vaccines and therapies.

Before the SARS-CoV-2 spike protein can interact with ACE2 on a human cell, it changes shape to expose its receptor binding domain (RBD), the part of the protein that interacts with ACE2. Like many viral proteins, the SARS-CoV-2 spike protein has a thick coat of glycans on its surface. These glycans, which are attached at specific sites, help shield the  from the host immune system. Rommie Amaro and colleagues at University of California San Diego, Maynooth University (Ireland) and the University of Texas at Austin wondered whether certain glycans in the SARS-CoV-2 spike protein might also be active players in the process leading to infection.

Image Credit:  AAdapted from ACS Central Science 2020, DOI: 10.1021/acscentsci.0c01056

Thanks to Heinz V. Hoenen and Frank Boehm.  Follow them on twitter: @HeinzVHoenen @cellrepair777

Read the whole article

News This Week

A potential milestone in cancer therapy

Researchers from the University of Bern, Inselspital, University Hospital Bern, and the University of Connecticut have made a significant breakthrough in the fight against cancer. They identified a previously unknown weak point of prostate [...]

Cancer and AI – Can ChatGPT Be Trusted?

A study published in the Journal of The National Cancer Institute Cancer Spectrum delved into the increasing use of chatbots and artificial intelligence (AI) in providing cancer-related information. The researchers discovered that these digital resources accurately [...]